MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas

(2012) N Gachard et al.   LEUKEMIA

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

(2012) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma

(2011) Manuel Montesinos-Rongen et al.   ACTA NEUROPATHOLOGICA

Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1

(2011) L. S. Hodge et al.   BLOOD

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

(2011) Steven P. Treon et al.   BRITISH JOURNAL OF HAEMATOLOGY

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

(2011) Xose S. Puente et al.   NATURE

Analysis of the coding genome of diffuse large B-cell lymphoma

(2011) Laura Pasqualucci et al.   NATURE GENETICS

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

Helical assembly in the MyD88–IRAK4–IRAK2 complex in TLR/IL-1R signalling

(2010) Su-Chang Lin et al.   NATURE

Identification of Critical Residues of the MyD88 Death Domain Involved in the Recruitment of Downstream Kinases

(2009) Maria Loiarro et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma

(2008) L. Arcaini et al.   ANNALS OF ONCOLOGY

Targeting NF- B in Waldenstrom macroglobulinemia

(2008) X. Leleu et al.   BLOOD

High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma

(2008) S. Montoto et al.   HAEMATOLOGICA

Sequential control of Toll-like receptor–dependent responses by IRAK1 and IRAK2

(2008) Tatsukata Kawagoe et al.   NATURE IMMUNOLOGY